Literature DB >> 10682076

Response to triple treatment with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori infections in continuous ambulatory peritoneal dialysis patients.

I Suleymanlar1, M Tuncer, M Tugrul Sezer, C Ertugrul, M Sarikaya, F Fevzi Ersoy, F Isitan, G Yakupoglu, G Suleymanlar.   

Abstract

In this study, the response to triple treatment with omeprazole, amoxicillin, and clarithromycin was investigated in continuous ambulatory peritoneal dialysis (CAPD) patients with Helicobacter pylori (Hp) infections. The study enrolled 20 CAPD patients (11 male, 9 female) who had dyspeptic complaints. The mean age of the patients was 46 (range: 21-65). The study also enrolled, as a control group, 124 patients (66 male, 58 female) who had no systemic disease, but who had upper gastrointestinal endoscopy for dyspeptic complaints. The mean age of the patients in the control group was 47 years (range: 20-74 years). Upper gastrointestinal endoscopy, rapid urease test (CLO test), and direct histologic examination were carried out to detect Hp infection. Hp infection was detected in 10 cases (50%) in the CAPD group and in 53 cases (43%) in the control group. In both groups, patients with Hp infection received the triple treatment of omeprazole 20 mg twice daily for 30 days, amoxicillin 500 mg thrice daily for 15 days, and clarithromycin 500 mg thrice daily for 15 days. To assess response to treatment, upper gastrointestinal endoscopy, CLO test, and direct histologic examination were repeated 3 months after initiation of the treatment. Hp was eradicated in all of the 11 CAPD patients (100%), and in 42 of the control patients (92%). Our results suggest that the triple treatment with omeprazole, amoxicillin, and clarithromycin for Hp infection is as effective in CAPD patients as in the normal population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10682076

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  1 in total

1.  Helicobacter pylori eradication for the treatment of dyspeptic symptoms in chronic renal failure.

Authors:  Miroslav Simunić; Dragan Ljutić; Stjepan Mise; Valdi Pesutić-Pisac; Marija Tonkić; Izet Hozo
Journal:  Ann Saudi Med       Date:  2005 Sep-Oct       Impact factor: 1.526

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.